All the news Showing 10 of 204 articles from: Finance, funding & health economicsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources WHA releases new messaging guide for Global Fund advocates World Hepatitis Alliance / 19 February 2021 Can investment in hepatitis C treatment be cost saving? Keith Alcorn / 24 November 2020 Direct-acting antiviral treatment for hepatitis C can be cost saving for some countries within five to ten years, especially if they can negotiate lower drug prices, a study presented online at this ... Developing an HCV Investment Case for Punjab (India) World Hepatitis Alliance / 28 July 2020 Pharma sells states on ‘Netflix Model’ to wipe out hep c. but at what price? MedCity News / 27 October 2019 How much can 'Netflix'-style pricing for hepatitis C drugs save? Keith Alcorn / 03 June 2019 A 'Netflix'-style pricing agreement that allows the Australian government to treat an unlimited number of people with hepatitis C for AU$1 billion may result in savings close to US$5 billion, according to ... Louisiana is creating a drug-price revolution The Hill / 21 May 2019 $51 billion price tag for eliminating hepatitis C by 2030 Keith Alcorn / 11 April 2019 To achieve hepatitis C elimination worldwide by 2030, governments, donors and the private sector will need to spend $51 billion but eliminating hepatitis C will lead to a $19 billion ... Louisiana picks drug company for hepatitis C treatment plan San Francisco Chronicle / 27 March 2019 Global fund for hepatitis prepares for rollout Devex / 27 February 2019 Generic DAAs achieve excellent cure rates in Egypt matching those of branded drugs at a fraction of the cost Michael Carter / 01 February 2019 Generic direct-acting antivirals (DAAs) are just as effective and safe as their branded equivalents for the treatment of chronic hepatitis C virus (HCV) infection, according to Egyptian research published in Liver International. Generics achieved ... ← First12345...21Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive